MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Teams From the Universtiy of Bamako, Mali and the NIH Visit Sanaria
Teams from the Bamako Malaria Research Training Center, University of Bamako, Mali and the Laboratory of Immunology and Vaccinology, National Institutes of Allergy and Infectious Diseases, NIH visited Sanaria to discuss progress on our collaboration on 5 clinical trials in Mali and 2 clinical trials in the U.S. of PfSPZ Vaccine and PfSPZ-CVac.
Nature Magazine News: Promising malaria vaccine to be tested in first large field trial – Declan Butler
The vaccine can confer up to 100% protection and will be tested in 2,100 people on the west African island of Bioko.
The Government of Equatorial Guinea, US Energy Companies, and Sanaria Sign Agreements to Extend Support for Clinical Development of PfSPZ Vaccine for Malaria and a Pathway Towards Malaria Elimination on Bioko Island
Sanaria Inc. and the Government of Equatorial Guinea last week signed an agreement that continues their joint commitment to develop Sanaria® PfSPZ Vaccine as a tool for malaria elimination. This follows a new, broader agreement between the Government of Equatorial Guinea (EG) and industry partners, Marathon Oil Corporation, Noble Energy Inc. and Atlantic Methanol Production Company (AMPCO), to sponsor clinical development of Sanaria® PfSPZ Vaccine, including the Phase 3 clinical program starting in 2020. This long standing, successful partnership highlights the unique involvement of an African government and private-sector energy companies in developing a vaccine for a largely African problem.
Dr. Martina Oneko wins best oral presentation award, of PfSPZ Vaccine, at the annual scientific conference of the Kenya Pediatric Association
Dr. Oneko, was the principal investigator of the KSPZV1 trials of Sanaria® PfSPZ Vaccine in Siaya, Kenya.
The International PfSPZ Consortium (I-PfSPZ-C)
Sanaria Inc. hosted the semi-annual International PfSPZ consortium (I-PfSPZ-C) meeting at Tulane University School of Public Health and Tropical Medicine in New Orleans, on November 1st and 2nd. This meeting was attended by 128 attendees from 43 institutions present in 16 countries, and more joining online from around the world, all to collaborate and strategize regarding Sanaria’s PfSPZ program.
Dr. Adel Mahmoud, Sanaria Board member, passes away
It is with great sadness that Sanaria shares the news of the passing of long standing Sanaria Board member, Dr. Adel Mahmoud. Dr. Mahmoud was a giant in the treatment and prevention of infectious diseases around the world. He died Monday, June 11, in New York City, age 76, from a brain hemorrhage.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.